Long-Term Outcomes of a Prospective Study on Magnetic Resonance Imaging-Guided Whole-Gland Salvage High-Dose-Rate Prostate Brachytherapy for Locally Recurrent Prostate Cancer

Purpose

Whole-gland salvage high-dose-rate (HDR) prostate brachytherapy is an emerging option for radiorecurrent prostate cancer. However, long-term prospective data remain limited. This report presents the long-term results of our prospective study on the toxicities, health-related quality of life, and efficacy of whole-gland HDR prostate brachytherapy. Methods and Materials: Patients with biopsy-confirmed, magnetic resonance (MR)-visible local recurrent prostate cancer after previous external beam radiation therapy (EBRT) were eligible. Patients underwent MR-assisted, ultrasound-based whole-gland HDR prostate brachytherapy with a prescription dose of 21 Gy to the entire prostate and 27 Gy to the MR-defined intraprostatic target volume (TV) divided over 2 implants separated by 1 to 2 weeks. Adjuvant androgen deprivation therapy was not used.